Prevalence and determinants of polypharmacy in Switzerland: Data from the CoLaus study

BMC Health Services Research

Volumn 17, Issue 1, 2017, Pages

  Castioni, Julien ^a   Marques Vidal, Pedro ^a   Abolhassani, Nazanin ^a   Vollenweider, Peter ^a   Waeber, Gérard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Epidemiology; Polypharmacy; Smoking; Socio economic

Indexed keywords

ADULT; AGE; AGED; BODY MASS; EDUCATIONAL STATUS; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; POLYPHARMACY; PREVALENCE; SMOKING; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BODY MASS INDEX; EDUCATIONAL STATUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVERWEIGHT; POLYPHARMACY; PREVALENCE; SMOKING;

EID: 85039056683     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-017-2793-z     Document Type: Article

References (47)

1. Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008. BMC Clin Pharmacol. 2010;10:16.
2. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818-31.
3. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13:74.
4. Pappa E, Kontodimopoulos N, Papadopoulos AA, Tountas Y, Niakas D. Prescribed-drug utilization and polypharmacy in a general population in Greece: association with sociodemographic, health needs, health-services utilization, and lifestyle factors. Eur J Clin Pharmacol. 2011;67(2):185-92.
5. Alzner R, Bauer U, Pitzer S, Schreier MM, Osterbrink J, Iglseder B. Polypharmacy, potentially inappropriate medication and cognitive status in Austrian nursing home residents: results from the OSiA study. Wiener medizinische Wochenschrift (1946). 2016;166(5-6):161-5.
6. Wauters M, Elseviers M, Vaes B, Degryse J, Dalleur O, Vander Stichele R, Van Bortel L, Azermai M. Polypharmacy in a Belgian cohort of community-dwelling oldest old (80+). Acta Clin Belg. 2016;71(3):158-66.
7. Mayer S, Osterle A. Socioeconomic determinants of prescribed and non-prescribed medicine consumption in Austria. Eur J Pub Health. 2015;25(4):597-603.
8. Pache B, Vollenweider P, Waeber G, Marques-Vidal P. Prevalence of measured and reported multimorbidity in a representative sample of the Swiss population. BMC Public Health. 2015;15:164.
9. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet (London, England). 2012;380(9836):37-43.
10. Walckiers D, Van der Heyden J, Tafforeau J. Factors associated with excessive polypharmacy in older people. Archives of public health = Archives belges de sante publique. 2015;73:50.
11. Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open. 2015;5(9):e008656.
12. Blozik E, Rapold R, von Overbeck J, Reich O. Polypharmacy and potentially inappropriate medication in the adult, community-dwelling population in Switzerland. Drugs Aging. 2013;30(7):561-8.
13. Payne RA, Avery AJ, Duerden M, Saunders CL, Simpson CR, Abel GA. Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol. 2014;70(5):575-81.
14. Hovstadius B, Astrand B, Petersson G. Dispensed drugs and multiple medications in the Swedish population: an individual-based register study. BMC Clin Pharmacol. 2009;9:11.
15. Charlesworth CJ, Smit E, Lee DS, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988-2010. The journals of gerontology Series A, Biological sciences and medical sciences. 2015;70(8):989-95.
16. Haider SI, Johnell K, Weitoft GR, Thorslund M, Fastbom J. The influence of educational level on polypharmacy and inappropriate drug use: a register-based study of more than 600,000 older people. J Am Geriatr Soc. 2009;57(1):62-9.
17. Gokce Kutsal Y, Barak A, Atalay A, Baydar T, Kucukoglu S, Tuncer T, Hizmetli S, Dursun N, Eyigor S, Saridogan M, et al. Polypharmacy in the elderly: a multicenter study. J Am Med Dir Assoc. 2009;10(7):486-90.
18. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213-8.
19. Cooper JA, Cadogan CA, Patterson SM, Kerse N, Bradley MC, Ryan C, Hughes CM. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ Open. 2015;5(12):e009235.
20. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65.
21. Schottker B, Saum KU, Muhlack DC, Hoppe LK, Holleczek B, Brenner H. Polypharmacy and mortality: new insights from a large cohort of older adults by detection of effect modification by multi-morbidity and comprehensive correction of confounding by indication. Eur J Clin Pharmacol. 2017
22. Cadogan CA, Ryan C, Hughes CM. Appropriate polypharmacy and medicine safety: when many is not too many. Drug Saf. 2016;39(2):109-16.
23. Patterson SM, Cadogan CA, Kerse N, Cardwell CR, Bradley MC, Ryan C, Hughes C: Interventions to improve the appropriate use of polypharmacy for older people. The Cochrane database of systematic reviews 2014(10):Cd008165.
24. Neuner-Jehle S. Polypharmacy, the new epidemic. Revue medicale suisse. 2016;12(518):942-7.
25. Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D, Paccaud F, Preisig M, Song KS, Yuan X, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord. 2008;8:6.
26. Antiochos P, Marques-Vidal P, McDaid A, Waeber G, Vollenweider P. Association between parental history and genetic risk scores for coronary heart disease prediction: the population-based CoLaus study. Atherosclerosis. 2016;244:59-65.
27. Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63(2):187-95.
28. Aubert CE, Streit S, Da Costa BR, Collet TH, Cornuz J, Gaspoz JM, Bauer D, Aujesky D, Rodondi N. Polypharmacy and specific comorbidities in university primary care settings. European journal of internal medicine. 2016
29. Gillette C, Prunty L, Wolcott J, Broedel-Zaugg K. A new lexicon for polypharmacy: implications for research, practice, and education. Research in social & administrative pharmacy: RSAP. 2015;11(3):468-71.
30. Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol. 2015;71(12):1415-27.
31. Topinkova E, Baeyens JP, Michel JP, Lang PO. Evidence-based strategies for the optimization of pharmacotherapy in older people. Drugs Aging. 2012;29(6):477-94.
32. Bardel A, Wallander MA, Svardsudd K. Reported current use of prescription drugs and some of its determinants among 35 to 65-year-old women in mid-Sweden: a population-based study. J Clin Epidemiol. 2000;53(6):637-43.
33. Davin C, Vollenweider P, Waeber G, Paccaud F, Marques-Vidal P. Cardiovascular risk factors attributable to obesity and overweight in Switzerland. Nutrition, metabolism, and cardiovascular diseases: NMCD. 2012;22(11):952-8.
34. Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176(4):473-82.
35. Danon-Hersch N, Marques-Vidal P, Bovet P, Chiolero A, Paccaud F, Pecoud A, Hayoz D, Mooser V, Waeber G, Vollenweider P. Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the CoLaus study. European journal of cardiovascular prevention and rehabilitation: official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2009;16(1):66-72.
36. Firmann M, Marques-Vidal P, Paccaud F, Mooser V, Rodondi N, Waeber G, Vollenweider P. Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go. European journal of cardiovascular prevention and rehabilitation: official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2010;17(6):682-7.
37. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al. 2013 ESH/ESC guidelines for the Management of Arterial Hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219.
38. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, et al. 2016 ESC/EAS guidelines for the Management of Dyslipidaemias: the task force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS)developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016
39. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C et al: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European journal of preventive cardiology 2016, 23(11):Np1-np96.
40. Messerli M, Blozik E, Vriends N, Hersberger KE. Impact of a community pharmacist-led medication review on medicines use in patients on polypharmacy - a prospective randomised controlled trial. BMC Health Serv Res. 2016;16(1):145.
41. Tamura BK, Bell CL, Lubimir K, Iwasaki WN, Ziegler LA, Masaki KH. Physician intervention for medication reduction in a nursing home: the polypharmacy outcomes project. J Am Med Dir Assoc. 2011;12(5):326-30.
42. Kojima G, Bell C, Tamura B, Inaba M, Lubimir K, Blanchette PL, Iwasaki W, Masaki K: Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. Journal of the American Medical Directors Association 2012, 13(9):818.e811-815.
43. Castellano JM, Sanz G, Penalvo JL, Bansilal S, Fernandez-Ortiz A, Alvarez L, Guzman L, Linares JC, Garcia F, D'Aniello F, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64(20):2071-82.
44. Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol. 2007;17(9):643-53.
45. Holbrook A, Bowen JM, Patel H, O'Brien C, You JJ, Tahavori R, Doleweerd J, Berezny T, Perri D, Nieuwstraten C, et al. Process mapping evaluation of medication reconciliation in academic teaching hospitals: a critical step in quality improvement. BMJ Open. 2016;6(12):e013663.
46. Sarzynski EM, Luz CC, Rios-Bedoya CF, Zhou S. Considerations for using the 'brown bag' strategy to reconcile medications during routine outpatient office visits. Qual Prim Care. 2014;22(4):177-87.
47. Drieling RL, LaCroix AZ, Beresford SA, Boudreau DM, Kooperberg C, Heckbert SR. Validity of self-reported medication use compared with pharmacy Records in a Cohort of older women: findings from the Women's Health Initiative. Am J Epidemiol. 2016;184(3):233-8.